Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The company acquired GH31 from Chinese firm Genhouse for $80 million up front and will test it in tumors with MTAP deletions.

The firm originally submitted a new drug application seeking approval of the drug in 2016, which was rejected, and, in 2024, resubmitted an application.

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Researchers are evaluating Lyell's CD19/20 dual-targeting CAR-T against marketed CD19 CAR T-cell therapies in the second-line refractory large B-cell lymphoma setting.

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Ultragenyx recently resubmitted a BLA seeking approval for the gene therapy after the FDA rejected it, and the firm will resubmit it again in response to new questions.